Brief: Gufic Biosciences Gets Approval To Make & Market Liposomal Amphotericin B Injection
20/05/2021 11:34
May 20 (Reuters) - Gufic Biosciences Ltd GUFI.NS :
* GOT REGULATOR NOD TO MAKE & MARKET LIPOSOMAL AMPHOTERICIN
B
INJECTION 50MG/VIAL (LYOPHILIZED)
* INJECTION IS USED TO TREAT CASES OF MUCORMYCOSIS
Source text for Eikon: ID:nBSE9BbZYQ
Further company coverage: GUFI.NS
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Gufic Biosciences
See all newsBrief: Gufic Biosciences Says USFDA Pre-Approval Inspection At Indore Facility
Brief: Gufic Biosciences June-Quarter Consol Total Profit 223.1 Million Rupees
Brief: Gufic Biosciences Receives Tax Demand Notice For 43.3 Million Rupees
Brief: Gufic Biosciences Receives Tax Demand Notice For 43.3 Million Rupees
Brief: Gufic Biosciences posts Sept-Quarter Consol Revenue From Operations 2.37 Billion Rupees